Drug manufacturer Eli Lilly plans to file retatrutide, its next-generation obesity drug, with the FDA in the first quarter of 2027. The drug targets three hormone receptors involved in appetite and metabolism: GLP-1, GIP and glucagon.
Kalshi lists a market on when the FDA will approve retatrutide, with separate contracts for approval before July 1, 2027, January 1, 2028 and July 1, 2028.
What’s Retatrutide and Will the FDA Approve It?
Retatrutide is not FDA-approved, and Lilly has not yet filed its application. Kalshi, a CFTC-regulated exchange, is one of several prediction market platforms listing the question. The drug is a triple agonist that targets three hormones:
- GLP-1 (appetite control)
- GIP (insulin/metabolism)
- Glucagon (energy expenditure)
In TRIUMPH-1, Lilly’s main Phase 3 obesity trial, adults on the highest dose lost an average of 28.3% of their body weight after 80 weeks. In TRIUMPH-2, which enrolled adults with type 2 diabetes, weight loss reached 20.8%, alongside lower A1C.
Now, as a trader on Kalshi, your job is to determine whether this drug is legitimate. The FDA is very rigorous in approving new drugs. In other words, you shouldn’t assume Retatrutide will receive approval simply because it has the allure of a miracle drug.
For a new drug like retatrutide, the FDA takes about 60 days to accept an application, then aims to decide within 10 months under a standard review or six months under a priority review.
Where Things Currently Stand with Retatrutide
Retatrutide has reported results from its main Phase 3 trials, the final stage of testing before an FDA filing. Lilly moved its planned submission from late 2026 to the first quarter of 2027 to gather more manufacturing and quality-control data. Lilly is also in a dispute with the FDA over whether retatrutide should be reviewed as a biologic, which would bring 12 years of market exclusivity instead of five.
- Company: Eli Lilly
- Drug Type: Triple agonist (GLP-1, GIP, glucagon)
- Treatment: Obesity, diabetes, and more
- Clinical Stage: Phase 3 complete, FDA filing Q1 2027
- Weight Loss Results: Up to 28.3% average (TRIUMPH-1, 80 weeks)
- Diabetes Impact: Up to 2.0%
What Traders Are Saying on Kalshi
On Kalshi, the contract for approval before July 1, 2027, traded at 44 cents on October 6, which implies a 44% chance. Contracts for approval before January 1, 2028, and July 1, 2028, implied about 87% and 90%, respectively. The market had about $47,000 in trading volume.
The price is likely to move on Lilly’s filing, the FDA’s acceptance of the application, and any decision on priority review.
NEXT’s pick is ‘No’ on the July 1, 2027 contract. Even with a filing early in the first quarter of 2027 and a six-month priority review, the FDA’s decision date would fall after July 2027. Only a faster pathway, such as a Commissioner’s National Priority Voucher, would change that, and none has been announced for retatrutide. Traders can sell a position before the market settles if the outlook changes.
Explore and Trade on Other Prediction Markets
Retatrutide’s approval isn’t the only prediction market out there. You can explore many different options involving economy predictions, entertainment predictions, and much more. You might choose to participate if you follow current events in politics, sports, and other areas of interest.
